This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Frederick L. Jones, Jr, MD; Norman L. Ekberg, MD
Geisinger Medical Center Danville, Pa

JAMA. 1980;244(24):2730.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Timolol maleate, a widely prescribed drug for treatment of glaucoma, is a nonselective β-adrenergic blocking agent. Its administration in the form of eyedrops to patients with obstructive airways disease may cause bronchoconstriction.¹ Hence, it is imperative that those caring for patients with glaucoma, ophthalmologists and primary care physicians alike, appreciate the potentially harmful systemic effects of this valuable drug. We have seen three patients whose obstructive airway disease was aggravated by timolol therapy.

Report of Cases.—CASE 1.—

A 68-year-old man with severe emphysema received a single dose of 0.25% timolol maleate eyedrops. Soon thereafter he became severely dyspneic and required hospitalization. On examination he showed signs of severe airway obstruction. After several hours of intensive treatment with aminophylline, terbutaline sulfate, and corticosteroids, his respiratory status returned to normal. He has had no further such attacks in the succeeding six months.

CASE 2.—

A 73-year-old . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?